, Volume 51, Issue 6, pp 974–980


  • Sanjay S. Patel
  • Michelle I. Wilde
New Drug Profile

DOI: 10.2165/00003495-199651060-00006

Cite this article as:
Patel, S.S. & Wilde, M.I. Drugs (1996) 51: 974. doi:10.2165/00003495-199651060-00006


▴ Ebrotidine is the first of a new generation of H2 receptor antagonists with gastroprotective activity

▴ It stimulates epithelial cell proliferative activity and produces beneficial physicochemical changes in the gastric mucus that contribute to its gastroprotective action against ethanol-, aspirin- or stress-induced gastric mucosal damage

▴ The antisecretory properties of ebrotidine are similar to those of ranitidine and ≈ 10-fold greater than those of Cimetidine

▴ This drug exhibits anti-Helicobacter pylori activity that is synergistic with a number of antibacterial agents; it inhibits the urease enzyme and the proteolytic and mucolytic activities of H. pylori, and counteracts the inhibitory effects of H. pylori lipopolysaccharide

▴ Ebrotidine is as effective as ranitidine for the treatment of patients with gastric or duodenal ulcers or erosive reflux oesophagitis

▴ Ebrotidine therapy results in significantly better ulcer healing rates than ranitidine treatment in patients who smoke.

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Sanjay S. Patel
    • 1
  • Michelle I. Wilde
    • 1
  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations